Multiple analysts have issued price targets for $REGN recently. We have seen 17 analysts offer price targets for $REGN in the last 6 months, with a median target of ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $838.07, a high estimate of $975.00, and a low estimate of $745.00. This upward trend is evident, ...

Regeneron (REGN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...

What a fantastic six months it’s been for Regeneron. Shares of the company have skyrocketed 47.6%, hitting $774.98. This was partly due to its solid quarterly results, and the performance may have ...

Why Regeneron Pharmaceuticals stock is on investor radar today Regeneron Pharmaceuticals (REGN) is drawing attention after a period in which its share price has moved between negative weekly returns ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 5.33% in ...

Here is why we believe Regeneron Pharmaceuticals (REGN) stock is worthy of consideration as a value investment. It is presently trading nearly 38% lower than its one-year peak, and is also being ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported upbeat fourth-quarter earnings. The company posted adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus ...